Inventiva SA (GB:0RNK)
LSE:0RNK
Earnings Data
Report Date
Sep 23, 2026During Market Hours (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.36Last Year’s EPS
-1.38Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasizes several substantial positives: completion of a large, well-powered Phase III enrollment, a strong cash position today, strategic focus on lanifibranor with monetization of non-core assets (odiparcil), regulatory designations (Breakthrough/Fast Track), and organizational strengthening. Key risks and negatives are manageable but material: readout timing into Q4 2026, conditionality of additional tranche funding, safety/tolerability attention on PPAR-related fluid retention/weight gain (though no CHF signal reported), and a competitive landscape (e.g., Madrigal) that increases the importance of a robust Phase III effect. On balance, operational and financial preparedness plus a large addressable market and prior Phase II efficacy signals outweigh the outstanding uncertainties, but the company’s future funding and commercial upside remain closely tied to the upcoming Phase III readout.Company Guidance
NATiV3 Enrollment Completed — Large, Well-Powered Trial
Enrollment for the global Phase III NATiV3 trial was completed in April 2025, exceeding original targets with over 1,000 patients in the main cohort (approximately 1,009 referenced) and an additional 410 patients in an exploratory F1–F4 cohort. The trial is powered >90% for the prespecified composite primary endpoint (fibrosis improvement ≥1 stage AND MASH resolution).
Top-Line Readout Timing Set
Company updated expected top-line readout timing to Q4 2026, reflecting sequencing of clinical and biostatistical milestones.
Strong Cash Position and Financing History
As of December 31, 2025, Inventiva reported EUR 230.9 million in cash, cash equivalents and short-term deposits. This position reflects two 2025 financings: ~EUR 108 million net from the May tranche and ~EUR 139.4 million net from the November U.S. registered public offering.
Cash Runway Extends Beyond NATiV3 Readout
Based on current operating plan and cost structure, Inventiva estimates a cash runway to mid-Q1 2027. If tranche 3 warrants are fully exercised, runway could extend to mid-Q3 2027 with potential additional proceeds up to EUR 116 million.
Pipeline Prioritization and Asset Monetization
Company strategically prioritized lanifibranor and sold global rights to odiparcil in Q4 2025 to Biossil. Transaction may yield up to USD/EUR 90 million in potential regulatory and commercial milestone payments plus potential high single-digit royalties on future net sales.
Clinical Differentiation and Prior Phase II Data
Lanifibranor is a balanced pan-PPAR agonist (alpha/delta/gamma) with prior Phase IIb NATIVE results showing a statistically significant composite endpoint improvement (24% treatment effect reported for the 1,200 mg dose at 6 months) and cited ~18% fibrosis improvement in Phase II. FDA granted Breakthrough Therapy and Fast Track designations based on Phase II data.
Favorable Secondary Clinical Signals
Phase II data showed metabolic benefits including HbA1c lowering of ~0.5 percentage points on average, triglyceride reduction and HDL increase, supportive of extra-hepatic benefits relevant to the diabetic F2/F3 segment.
Organizational Strengthening and Regulatory/Commercial Readiness
Key leadership hires added in 2025 (CMO/President of R&D, EVP Head of Quality & Regulatory Affairs, Chief Commercial Strategy Officer). Company reports regulatory, quality and early commercial readiness work is underway while maintaining a lean commercial build until positive data.
Trial Operational Quality Controls
Company reports robust biopsy quality-control processes, blinded reading procedures, ongoing monitoring and demonstrated early termination rates below the 30% covenant threshold used in financing covenants, supporting trial integrity and powering assumptions.
Large Addressable Market and Improving Diagnosis
Company cites an estimated ~18 million people in the U.S. with MASH, only ~10% currently diagnosed (diagnosed estimate up ~25% vs. 2024), and among diagnosed with clinically actionable F2/F3 disease only ~40% are under care — indicating a growing and underpenetrated market opportunity.
GB:0RNK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0RNK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 30, 2026 | €4.75 | €4.39 | -7.57% |
Sep 29, 2025 | €4.97 | €5.03 | +1.17% |
Mar 26, 2025 | €2.74 | €2.74 | 0.00% |
Sep 25, 2024 | €1.88 | €1.88 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Inventiva SA (GB:0RNK) report earnings?
Inventiva SA (GB:0RNK) is schdueled to report earning on Sep 23, 2026, During Market Hours (Confirmed).
What is Inventiva SA (GB:0RNK) earnings time?
Inventiva SA (GB:0RNK) earnings time is at Sep 23, 2026, During Market Hours (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Inventiva SA stock?
The P/E ratio of Inventiva is N/A.
What is GB:0RNK EPS forecast?
GB:0RNK EPS forecast for the fiscal quarter 2026 (Q2) is -0.36.